YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Capecitabine
Related studies linked through entity extraction aliases.
Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
- Status
- RECRUITING
- Phase
- PHASE2
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Status
- RECRUITING
- Phase
- PHASE3
SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.
- Status
- RECRUITING
- Phase
- PHASE2
A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2